Effect of N-acetylcysteine on renal function in patients with chronic kidney disease

Nephrology

Volumn 12, Issue 5, 2007, Pages 510-513

  Mainra, Rahul ^a   Gallo, Kerri ^a   Moist, Louise ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b Department of Medicine and Epidemiology ^*  (Canada)

Author keywords

Chronic kidney disease; Cystatin C; N acetylcysteine; Renal function

Indexed keywords

ACETYLCYSTEINE; CIMETIDINE; CREATININE; CYSTATIN C;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DRUG EFFECT; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE;

ACETYLCYSTEINE; AGED; CHRONIC DISEASE; CIMETIDINE; CREATININE; CYSTATINS; DRUG SYNERGISM; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; TIME FACTORS;

EID: 34548433887     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00833.x     Document Type: Article

References (28)

1. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ 2005 172 : 1461 71.
2. Pannu N, Tonelli M. Strategies to reduce the risk of contrast nephropathy: An evidence-based approach. Curr. Opin. Nephrol. Hypertens. 2006 15 : 285 90.
3. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 2006 354 : 379 86.
4. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int. 2006 100 (Suppl S11 15.
5. Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. Rev. Cardiovasc. Med. 2003 4 (Suppl 5 S10 18.
6. Mccullough P. Outcomes of contrast-induced nephropathy: Experience in patients undergoing cardiovascular intervention. Catheter. Cardiovasc. Interv. 2006 67 : 335 43.
7. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney Int. 2006 100 (Suppl S8 10.
8. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005 68 : 14 22.
9. Goldenberg I, Shechter M, Matetzky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur. Heart J. 2004 25 : 212 18.
10. Miner SE, Dzavik V, Nguyen-Ho P et al. N-Acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am. Heart J. 2004 148 : 690 95.
11. Briguori C, Marenzi G. Contrast-induced nephropathy: Pharmacological prophylaxis. Kidney Int. 2006 100 (Suppl S30 38.
12. Tepel M, van der GM, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 2000 343 : 180 84.
13. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 2003 289 : 553 8.
14. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol. 2002 40 : 1383 8.
15. Hoffmann U, Fischereder M, Kruger B et al. The value of N-Acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J. Am. Soc. Nephrol. 2004 15 : 407 10.
16. Hervey GR. Determination of creatinine by the Jaffe reaction. Nature 1953 171 : 1125.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
18. Rule AD, Larson TS, Bergstralh EJ et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann. Intern. Med. 2004 141 : 929 37.
19. Bauer JH, Brooks CS, Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. Am. J. Kidney Dis. 1982 2 : 337 46.
20. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am. J. Kidney Dis. 1998 32 : 23 31.
21. Hilbrands LB, Artz MA, Wetzels JF et al. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int. 1991 40 : 1171 6.
22. Tenstad O, Roald AB, Grubb A et al. Renal handling of radiolabelled human cystatin C in the rat. Scand. J. Clin. Lab. Invest. 1996 56 : 409 14.
23. Borgstrom L, Kagedal B. Dose dependent pharmacokinetics of N-Acetylcysteine after oral dosing to man. Biopharm. Drug Dispos. 1990 11 : 131 6.
24. Holdiness MR. Clinical pharmacokinetics of N-Acetylcysteine. Clin. Pharmacokinet 1991 20 : 123 34.
25. Hussain AS, Day A, Pilkey R, Yeates K. N-acety cysteine does not acutely alter serum creatinine levels in patients with chronic kidney disease prior to coronary angiography [Abstract]. J. Am. Soc. Nephrol. 2004 15 : SA PO218.
26. Izzedine H, Guerin V, Launay-Vacher V et al. Effect of N-Acetylcysteine on serum creatinine level. Nephrol. Dial. Transplant. 2001 16 : 1514 15.
27. Toprak O. Interactions between serum creatinine, volume status, N-Acetylcysteine, and contrast-induced nephropathy. Ren. Fail. 2006 28 : 265 6.
28. Genet S, Kale RK, Baquer NZ. Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol. Cell Biochem. 2000 210 : 23 8.